Research programme: cancer therapeutics - ArQule/Beryllium

Drug Profile

Research programme: cancer therapeutics - ArQule/Beryllium

Latest Information Update: 11 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ArQule; Beryllium
  • Class Small molecules
  • Mechanism of Action Programmed cell death-1 ligand-1inhibitors; Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 04 Nov 2016 ArQule and Beryllium jointly terminate the research and development agreement for programmed cell death protein and ligand inhibitors in Cancer (ArQule's form 10-K, filed in March 2017)
  • 04 Nov 2016 Discontinued for Cancer in USA, as the agreement between the companies was terminated (ArQule's form 10-K, filed in March 2017)
  • 20 May 2015 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top